content

Arven Pharmaceuticals selects GE Healthcareโ€™s FlexFactory to improve Turkish and regional access to biopharmaceuticals

Arven Pharmaceuticals, a Toksoz Group Company, has selected GE Healthcareโ€™s FlexFactory manufacturing platform to expand production capacity at its facility in Kirklareli, Turkey. ...

MeiraGTx Awarded Target ALS Grant For Its NMD-Based Therapy for ALS

MeiraGTx, a New York and UK based gene therapy company, announced that it has been awarded a grant from Target ALS, a privately funded...

Sanofi and Regeneron Announce First ย Approval of KevzaraTM for the Treatment of Moderately

Sanofi and Regeneron Pharmaceuticals, Inc announced that Health Canada approved KevzaraTM (sarilumab), an interleukin-6 (IL-6) receptor antibody. For the treatment of...

MDCPartners launches new ta-Scan software that โ€˜will revolutionizeโ€™ the way pharmaceutical companies plan for the future

MDCPartners ย launches ta-Scan 5, an update of its global web-based platform that analyses clinical trial data. The new platform is set to revolutionize the...

Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m in new research centre

University of Oxford and Novo Nordisk announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk...

Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial

ย Astellas Pharma Inc and Ironwood Pharmaceuticals Inc announced top-line results indicating that the Phase III clinical trial of linaclotide conducted in Japan in adults...

Mallinckrodt Completes Sale Of Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million

Mallinckrodt plc , a leading specialty pharmaceutical company, announced today that it has closed the sale of its global Nuclear Imaging business to IBA...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read